Loading…
5 companies · GEL, thousands · columns ordered by revenue
Only 3 of 5 peers filed FY2024. Switch to FY2021 (5 of 5).
| Line item | Ji-I-Es-Ei Parmatsevtik… | New Parm Group | Asemod | Parmahabi | Zi Portres Group Kompani |
|---|---|---|---|---|---|
| Total Revenue | 5,654 | 5,536 | 5,423 | — | — |
| Total COGS | -2,863 | -1,960 | -3,546 | — | — |
| Gross Profit | 2,791 | 3,576 | 1,877 | — | — |
| Gross Margin | 49.4% | 64.6% | 34.6% | — | — |
| Total Operating Expenses | -54 | -2,019 | -500 | — | — |
| EBITDA | 2,737 | 1,558 | 1,377 | — | — |
| EBITDA Margin | 48.4% | 28.1% | 25.4% | — | — |
| Total D&A | 0 | -39 | -6 | — | — |
| EBIT / Operating Income | 2,737 | 1,519 | 1,372 | — | — |
| Total Interest Expense | -16 | -23 | -0 | — | — |
| Total Other Income | -100 | — | -33 | — | — |
| Profit Before Tax | 2,621 | 1,496 | 1,339 | — | — |
| Total Income Tax | 0 | -172 | -62 | — | — |
| Net Profit / (Loss) | 2,621 | 1,324 | 1,275 | — | — |
| Net Margin | 46.4% | 23.9% | 23.5% | — | — |
Not every picked company reports every selected year — FY2024: no filing for Parmahabi and Zi Portres Group Kompani. Those cells are left blank (no filing), not zero.
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Ji-I-Es-Ei Parmatsevtik… | Pharma | 48.4% | 95th pct | 110 |
| New Parm Group | Pharma | 28.1% | 73rd pct | 110 |
| Asemod | Pharma | 25.4% | 68th pct | 110 |
| Parmahabi | Pharma | — | no FY data | 110 |
| Zi Portres Group Kompani | Pharma | — | no FY data | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.